Also listed under Dementia
ClinicalTrials.gov term: Alzheimer Disease
71 trials changed in the last 30 days: 3 stopped, 35 with notable changes, 33 with minor changes only.
Trial terminated
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to May 14, 2026
GlaxoSmithKlinePhase 2 NCT06079190 Registry history of NCT06079190 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Suspended
Also in this update: Primary completion pushed from Jan 2027 to Nov 2027; Primary endpoint(s) modified
Poitiers University HospitalNot applicable NCT06902753 Registry history of NCT06902753 on ClinicalTrials.gov (opens the registry)
Trial status changed: Enrolling by Invitation → Withdrawn
Emory UniversityNot applicable NCT05139290 Registry history of NCT05139290 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 2026 to Mar 2028
Also in this update: Study completion pushed from Jun 2027 to Jun 2028
NKGen Biotech, Inc.Phase 1/2 NCT06189963 Registry history of NCT06189963 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 30, 2026 to Apr 30, 2027
Also in this update: Study completion pushed from Sep 30, 2026 to Sep 30, 2027
Herrick Medical LLCNot applicable NCT06862557 Registry history of NCT06862557 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 30, 2025 to Jun 30, 2027
Also in this update: Study completion pushed from Sep 30, 2026 to Sep 30, 2027
Herrick Medical LLCNot applicable NCT05295615 Registry history of NCT05295615 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Dec 2026 to Dec 31, 2027
Douglas ScharreNot specified NCT03019757 Registry history of NCT03019757 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Oct 1, 2026 to Oct 1, 2027
Heinrich-Heine University, DuesseldorfNot specified NCT06313944 Registry history of NCT06313944 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 28, 2026 to Nov 28, 2027
Also in this update: Study completion pushed from Oct 2026 to Mar 30, 2028
Cedars-Sinai Medical CenterNot applicable NCT07224607 Registry history of NCT07224607 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Study completion moved earlier from Dec 2027 to Oct 2027
AriBio Co., Ltd.Phase 3 NCT05531526 Registry history of NCT05531526 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Dec 2025 to Mar 2027
Monash UniversityNot specified NCT06339190 Registry history of NCT06339190 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Apr 30, 2026 to Sep 30, 2029
Also in this update: Enrollment reopened; Study completion pushed from Nov 1, 2026 to Nov 30, 2029
Aristotle University Of ThessalonikiNot applicable NCT06705738 Registry history of NCT06705738 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Sep 2026 to Sep 2031
Washington University School of MedicineNot specified NCT00869817 Registry history of NCT00869817 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Study completion pushed from Apr 30, 2029 to Apr 30, 2030
Merck Sharp & Dohme LLCPhase 2 NCT07033494 Registry history of NCT07033494 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Apr 30, 2026 to Dec 30, 2026
Also in this update: Enrollment closed, study ongoing
HudsonAlpha Institute for BiotechnologyNot applicable NCT07146412 Registry history of NCT07146412 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Trial completed; Primary completion date changed from estimate of Dec 2026 to Mar 6, 2026
Elixiron Immunotherapeutics Inc.Phase 2 NCT06745583 Registry history of NCT06745583 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Trial completed; Primary completion date changed from estimate of Nov 30, 2026 to Sep 16, 2026
University of Maryland, BaltimoreNot specified NCT04201600 Registry history of NCT04201600 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Institute for Molecular MedicinePhase 2 NCT07827768 Registry history of NCT07827768 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
The Methodist Hospital Research InstitutePhase 1/2 NCT07651319 Registry history of NCT07651319 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Trial sites expanded: 18 → 22 locations
Stichting International Registry for Alzheimer's Disease and other Dementias FoundationNot specified NCT07213700 Registry history of NCT07213700 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of May 31, 2026 to Sep 30, 2025; Final enrollment: 50 participants (planned 70)
HiDO TechnologiesPhase 2 NCT06691256 Registry history of NCT06691256 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion moved earlier from Jun 7, 2028 to Feb 16, 2028; Final enrollment: 1101 participants (planned 800)
Hoffmann-La RochePhase 3 NCT07169578 Registry history of NCT07169578 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 150 → 147 locations; Primary and study completion moved earlier from Jun 7, 2028 to Feb 16, 2028
Hoffmann-La RochePhase 3 NCT07170150 Registry history of NCT07170150 on ClinicalTrials.gov (opens the registry)
Primary and study completion pushed from Jul 2030 to Sep 2030
Also in this update: Trial sites expanded: 9 → 12 locations; Start date pushed from Oct 2026 to Nov 2026
Eli Lilly and CompanyPhase 4 NCT07838155 Registry history of NCT07838155 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Aug 2026 to Nov 2026; Trial sites reduced: 31 → 28 locations
IGC Pharma, LLCPhase 2 NCT05543681 Registry history of NCT05543681 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Aug 2026 to Jun 25, 2026; Final enrollment: 7 participants (planned 18)
Regeneration Biomedical, Inc.Phase 1 NCT05667649 Registry history of NCT05667649 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Also in this update: Primary completion date changed from estimate of Jul 2026 to Sep 28, 2026; Final enrollment: 43 participants (planned 62)
University of SalamancaNot applicable NCT07388186 Registry history of NCT07388186 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Eisai Inc.Not specified NCT07723950 Registry history of NCT07723950 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Poitiers University HospitalNot applicable NCT05939362 Registry history of NCT05939362 on ClinicalTrials.gov (opens the registry)
Trial completed
Massachusetts General HospitalNot applicable NCT07424443 Registry history of NCT07424443 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Final enrollment: 86 participants (planned 180)
Weill Medical College of Cornell UniversityPhase 2 NCT03649724 Registry history of NCT03649724 on ClinicalTrials.gov (opens the registry)
Trial completed
University of FloridaPhase 2 NCT04018092 Registry history of NCT04018092 on ClinicalTrials.gov (opens the registry)
Trial status changed: Recruiting → Not Yet Recruiting
Baylor College of MedicineNot applicable NCT06835283 Registry history of NCT06835283 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 154 → 157 locations
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 3 NCT06126224 Registry history of NCT06126224 on ClinicalTrials.gov (opens the registry)
Trial status changed: Unknown → Completed
Also in this update: Final enrollment: 7 participants (planned 28)
Washington State UniversityNot applicable NCT06397339 Registry history of NCT06397339 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Primary completion moved earlier from May 31, 2027 to Apr 30, 2027; Final enrollment: 101 participants (planned 120)
University of PittsburghNot applicable NCT06565169 Registry history of NCT06565169 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Kaiser PermanenteNot applicable NCT06362824 Registry history of NCT06362824 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 34 locations
Hoffmann-La RochePhase 3 NCT07717411 Registry history of NCT07717411 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 3 → 10 locations
Alnylam PharmaceuticalsPhase 2 NCT07636811 Registry history of NCT07636811 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 293 → 296 locations
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyPhase 3 NCT06585787 Registry history of NCT06585787 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 212 → 229 locations
Hoffmann-La RochePhase 3 NCT07177352 Registry history of NCT07177352 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 55 → 62 locations
MapLight TherapeuticsPhase 2 NCT06887192 Registry history of NCT06887192 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 14 → 20 locations
Alpha Cognition, IncPhase 4 NCT07633470 Registry history of NCT07633470 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 1 → 11 locations
SanofiPhase 2 NCT07688213 Registry history of NCT07688213 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 15 locations
Eli Lilly and CompanyPhase 1 NCT07598370 Registry history of NCT07598370 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 10 → 16 locations
Eli Lilly and CompanyPhase 1 NCT07787182 Registry history of NCT07787182 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 2026 to Oct 2026
Callahan-Young LLC DBA JigsawdioNot applicable NCT07839286 Registry history of NCT07839286 on ClinicalTrials.gov (opens the registry)
Start date pushed from Oct 1, 2026 to Oct 14, 2026
University Hospitals Cleveland Medical CenterPhase 1 NCT07531940 Registry history of NCT07531940 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Feb 2027 to Jun 2027
Dartmouth-Hitchcock Medical CenterNot applicable NCT07631247 Registry history of NCT07631247 on ClinicalTrials.gov (opens the registry)
Study completion pushed from Jul 31, 2026 to May 31, 2027
Rush University Medical CenterNot applicable NCT04337255 Registry history of NCT04337255 on ClinicalTrials.gov (opens the registry)
Study completion moved earlier from Feb 1, 2028 to Feb 2027
Also in this update: Primary completion moved earlier from Aug 1, 2027 to Feb 2027
Yale UniversityNot applicable NCT07602283 Registry history of NCT07602283 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Danish Dementia Research CentreNot specified NCT06621758 Registry history of NCT06621758 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
IRCCS Centro San Giovanni di Dio FatebenefratelliNot applicable NCT05730023 Registry history of NCT05730023 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-13 | NCT07871487 Tau Pathology in the Brain After Hip or Knee Replacement Surgery | Uppsala University Hospital new | |
| 2026-10-13 | NCT07870070 Functionalized Point of Care and 3D Printed Dental Aligners as Devices for Early… | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico new | |
| 2026-10-09 | NCT07869264 An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan | Eisai Taiwan Inc. new | |
| 2026-10-09 | NCT07869238 Pilot Clinical Trial to Assess the Safety of NMS-01 in Patients With Mild to Moderate… | Neumous Inc. new | |
| 2026-10-07 | NCT07863011 Exploratory Study of Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Patients… | ReadyCure Inc. new | |
| 2026-10-05 | NCT07857759 Cervical Lymphatic Microsurgery in Alzheimer's Disease | Daniel Maliszewski new | |
| 2026-10-02 | NCT07854327 Restoring Cervical Lymphatic Drainage in Alzheimer's Disease | University of Siena new | |
| 2026-09-25 | NCT07842146 The Effect of Urolithin A (Mitopure®) on Alzheimer's Disease | University Hospital, Akershus new | |
| 2026-09-25 | NCT07841808 Precuneus Mapping With Sinaptistim® (an Investigational TMS-EEG System) in Mild to… | Sinaptica Therapeutics, Inc. new | |
| 2026-09-24 | NCT07839286 Jigsawdio Multisensory Platform for People With Mild Cognitive Impairment, Alzheimer's… | Callahan-Young LLC DBA Jigsawdio new |
| Early Phase 1 | 17 | |
| Phase 1 | 64 | |
| Phase 1/2 | 30 | |
| Phase 2 | 110 | |
| Phase 2/3 | 13 | |
| Phase 3 | 58 | |
| Phase 4 | 19 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT07633470 | A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver… | Alpha Cognition, Inc | Recruiting | 2026-09-25 |
| NCT07688460 | Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's… | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | 2026-07-07 |
| NCT05924425 | Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to… | University Hospital, Montpellier | Recruiting | 2026-06-25 |
| NCT07604896 | Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through… | First Affiliated Hospital of Wenzhou Medical University | Recruiting | 2026-05-22 |
| NCT07502560 | A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia… | GlaxoSmithKline | Recruiting | 2026-05-12 |
| NCT05004987 | Aβ Dynamics in LLMD | NYU Langone Health | Recruiting | 2026-05-06 |
| NCT03821857 | Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease | Mayo Clinic | Recruiting | 2025-11-24 |
| NCT05908695 | An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of… | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Recruiting | 2023-11-09 |
| NCT03082755 | Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease | University of Texas at Austin | Recruiting | 2022-05-18 |
| NCT07838155 | A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's… | Eli Lilly and Company | Not Yet Recruiting | 2026-10-15 |
| NCT07579689 | Effects of Ginkgo Biloba on Blood Biomarkers in Mild Cognitive Impairment | Hanyang University | Not Yet Recruiting | 2026-06-26 |
| NCT00950430 | Imaging of Brain Amyloid Plaques in the Aging Population | Mayo Clinic | Enrolling by Invitation | 2026-06-23 |
| NCT06911944 | Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation | Michael Rafii, MD, PhD | Not Yet Recruiting | 2026-05-15 |
| NCT07034222 | 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease | Ruijin Hospital | Active, Not Recruiting | 2025-06-24 |
| NCT05586750 | Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy | Monash University | Active, Not Recruiting | 2025-05-22 |
| NCT01606488 | Effects of Brain Beta-Amyloid on Postoperative Cognition | University of California, San Francisco | Active, Not Recruiting | 2025-05-01 |
| NCT05058040 | A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Active, Not Recruiting | 2025-01-24 |
| NCT05181475 | Long-term Efficacy and Safety Study of GV-971 | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Active, Not Recruiting | 2024-11-15 |
| NCT03454646 | Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL) | University Hospital, Bordeaux | Not Yet Recruiting | 2023-10-06 |
| Phase 3 | ||||
| NCT05980949 | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in… | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Recruiting | 2026-10-16 |
| NCT06126224 | A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated… | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Recruiting | 2026-10-16 |
| NCT06937229 | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in… | Bristol-Myers Squibb | Recruiting | 2026-10-16 |
| NCT07011732 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment… | Bristol-Myers Squibb | Recruiting | 2026-10-15 |
| NCT07177352 | Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's… | Hoffmann-La Roche | Recruiting | 2026-10-15 |
| NCT07717411 | A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to… | Hoffmann-La Roche | Recruiting | 2026-10-13 |
Eli Lilly and Company (19) · Xuanwu Hospital, Beijing (18) · Washington University School of Medicine (15) · Mayo Clinic (11) · Indiana University (10) · Johns Hopkins University (9) · University of Pennsylvania (9) · Assistance Publique - Hôpitaux de Paris (8) · Bristol-Myers Squibb (8) · Hoffmann-La Roche (8)